无重度OSA的肥胖低通气综合征长期无创通气:Pickwick随机对照试验
这项西班牙16中心多中心开放标签平行组随机对照试验纳入98例未治疗、呼吸暂停低通气指数<30次/h的稳定期肥胖低通气综合征(OHS)门诊患者,比较无创通气(NIV)与生活方式干预。中位随访4.98年,两组年均住院天数无显著差异,但NIV组在PaCO2、pH、碳酸氢盐、生活质量和日间嗜睡方面有显著纵向改善;依从性高的亚组首次住院、急诊就诊和死亡时间更晚。
要点
- 无重度OSA的OHS患者中,NIV未显著减少长期住院天数。
- NIV可改善PaCO2、pH、碳酸氢盐、生活质量和日间嗜睡。
- 提高NIV依从性可能带来更好结局,值得强化依从性管理。
核心结论
- 在无重度OSA的稳定期OHS门诊患者中,NIV与生活方式干预的长期年均住院天数相似。
- 旨在提高NIV依从性的更强化方案可能带来更好结局。
- 仍需更大规模研究以更好确定该OHS亚组中NIV的长期获益。
研究设计与样本
- 多中心、开放标签、平行组随机对照临床试验,在西班牙16个中心开展。
- 共随机98例未治疗、稳定的OHS门诊患者,呼吸暂停低通气指数<30次/h(即无重度OSA)。
- 采用简单随机化经电子数据库分为NIV组或生活方式干预(对照组);NIV组与对照组各随机49例,各分析48例。
- 研究因难以识别无重度OSA的OHS患者而在第8年提前终止。
- 分析按意向治疗和符合方案原则进行,并做依从性亚组分析。
主要发现
- 与对照组相比,NIV在PaCO2、pH、碳酸氢盐、生活质量(SF-36躯体成分)和日间嗜睡方面有显著纵向改善。
- 符合方案分析显示,至首次急诊就诊的时间在NIV组有统计学显著差异并 favoring NIV。
- 高NIV依从性亚组至首次住院、急诊就诊和死亡事件的时间长于低依从性亚组。
- 两组不良事件相似。
临床怎么用
- 对无重度OSA的稳定期OHS患者,不应仅以减少住院天数为目标而期望NIV带来明确获益。
- NIV可考虑用于改善PaCO2、酸碱状态、生活质量和日间嗜睡。
- 应重视并强化NIV依从性管理,依从性高者住院、急诊和死亡事件时间可能更晚。
局限性
- 研究因难以识别无重度OSA的OHS患者而在第8年提前终止。
- 为开放标签设计,研究者和患者均知晓治疗分配。
- 样本量较小(每组分析48例)。
- 需要更大规模研究进一步确定该亚组中NIV的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noninvasive ventilation (NIV) is an effective form of treatment in obesity hypoventilation syndrome (OHS) with severe OSA. However, there is paucity of evidence in patients with OHS without severe OSA phenotype. RESEARCH QUESTION: Is NIV effective in OHS without severe OSA phenotype? STUDY DESIGN AND METHODS: In this multicenter, open-label parallel group clinical trial performed at 16 sites in Spain, we randomly assigned 98 stable ambulatory patients with untreated OHS and apnea-hypopnea index < 30 events/h (ie, no severe OSA) to NIV or lifestyle modification (control group) using simple randomization through an electronic database. The primary end point was hospitalization days per year. Secondary end points included other hospital resource utilization, incident cardiovascular events, mortality, respiratory functional tests, BP, quality of life, sleepiness, and other clinical symptoms. Both investigators and patients were aware of the treatment allocation; however, treating physicians from the routine care team were not aware of patients' enrollment in the clinical trial. The study was stopped early in its eighth year because of difficulty identifying patients with OHS without severe OSA. The analysis was performed according to intention-to-treat and per-protocol principles and by adherence subgroups. RESULTS: Forty-nine patients in the NIV group and 49 in the control group were randomized, and 48 patients in each group were analyzed. During a median follow-up of 4.98 years (interquartile range, 2.98-6.62), the mean hospitalization days per year ± SD was 2.60 ± 5.31 in the control group and 2.71 ± 4.52 in the NIV group (adjusted rate ratio, 1.07; 95% CI, 0.44-2.59; P = .882). NIV therapy, in contrast with the control group, produced significant longitudinal improvement in Paco2, pH, bicarbonate, quality of life (Medical Outcome Survey Short Form 36 physical component), and daytime sleepiness. Moreover, per-protocol analysis showed a statistically significant difference for the time until the first ED visit favoring NIV. In the subgroup with high NIV adherence, the time until the first event of hospital admission, ED visit, and mortality was longer than in the low adherence subgroup. Adverse events were similar between arms. INTERPRETATION: In stable ambulatory patients with OHS without severe OSA, NIV and lifestyle modification had similar long-term hospitalization days per year. A more intensive program aimed at improving NIV adherence may lead to better outcomes. Larger studies are necessary to better determine the long-term benefit of NIV in this subgroup of OHS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01405976; URL: www.clinicaltrials.gov.
引用
- Masa JF, Benítez I, Sánchez-Quiroga MÁ, et al. Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA: The Pickwick Randomized Controlled Trial. Chest. 2020. PMID: 32343963. doi:10.1016/j.chest.2020.03.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。